H. Becker

TL;DR: The detection of anti‐CCP is useful for the diagnosis of RA because of its similar sensitivity but higher specificity compared with RF, and also helps to diagnose other inflammatory and noninflammatory diseases by reducing the rate of false‐positive results in comparison with RF.

TL;DR: Treatment with MPS resulted in significant reduction of hypergammaglobulinemia and rheumatoid factors as well as an increase of complement levels and white blood cells, and MPS promises to be an additional therapeutic option for patients with pSS, at least in those with shorter disease duration.

TL;DR: Differences between MMF and CYC with regard to the mechanism of action are indicated, which leads to a fast and enduring reduction of surrogate markers of B cell activation, such as circulating plasmablasts, plasma cells and free light chains but a comparable rate of hypogammaglobulinemia.

TL;DR: The increased systemic secretion of IL1β and TNFα in patients with pSS points to a pathogenic impact of these cytokines in this autoimmune disease and indicates that IL1 β is a crucial regulator in the development of local and systemic disease manifestations.

TL;DR: This pilot study shows the feasibility of MSOT imaging to resolve microvascular dysfunction in SSc as a marker of disease activity and might help to grade SSc non‐invasively and monitor early therapy response.